ValuEngine Downgrades Alphatec (NASDAQ:ATEC) to Hold

Alphatec (NASDAQ:ATEC) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Thursday, ValuEngine reports.

Separately, Zacks Investment Research raised Alphatec from a “sell” rating to a “hold” rating in a research report on Monday, May 13th.

Alphatec stock traded up $0.03 on Thursday, hitting $4.80. 284,570 shares of the stock traded hands, compared to its average volume of 496,592. The company has a debt-to-equity ratio of 3.59, a quick ratio of 1.18 and a current ratio of 2.45. The stock has a market capitalization of $223.99 million, a price-to-earnings ratio of -8.28 and a beta of 1.47. The firm has a fifty day moving average of $4.57. Alphatec has a 1 year low of $1.18 and a 1 year high of $5.46.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Wednesday, July 24th. The medical technology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.05). The firm had revenue of $27.32 million for the quarter, compared to analysts’ expectations of $25.37 million. Alphatec had a negative net margin of 45.29% and a negative return on equity of 211.15%. On average, equities analysts forecast that Alphatec will post -0.65 EPS for the current year.

In other news, CFO Jeffrey G. Black sold 8,929 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $4.75, for a total transaction of $42,412.75. Following the completion of the transaction, the chief financial officer now directly owns 511,862 shares in the company, valued at $2,431,344.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Craig E. Hunsaker sold 50,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $4.50, for a total value of $225,000.00. The disclosure for this sale can be found here. Insiders have sold 108,929 shares of company stock valued at $517,413 over the last 90 days. Corporate insiders own 34.32% of the company’s stock.

Several large investors have recently modified their holdings of the company. Advisor Group Inc. bought a new stake in shares of Alphatec during the 2nd quarter valued at approximately $36,000. Royce & Associates LP grew its holdings in shares of Alphatec by 728.6% during the 1st quarter. Royce & Associates LP now owns 290,000 shares of the medical technology company’s stock valued at $768,000 after purchasing an additional 255,000 shares during the last quarter. Penn Capital Management Co. Inc. bought a new stake in shares of Alphatec during the 1st quarter valued at approximately $1,261,000. Suntrust Banks Inc. bought a new stake in shares of Alphatec during the 4th quarter valued at approximately $58,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Alphatec by 8.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 95,662 shares of the medical technology company’s stock valued at $219,000 after purchasing an additional 7,705 shares during the last quarter. Hedge funds and other institutional investors own 14.82% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.

Further Reading: Does a trade war provide a risk to the global economy?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.